957 filings
Page 5 of 48
S-8 POS
u9a 1bf5bgsrdnpsqv
20 Dec 19
Registration of securities for employees (post-effective amendment)
1:30pm
S-8 POS
ohd2a67c61
20 Dec 19
Registration of securities for employees (post-effective amendment)
1:28pm
S-8 POS
ay9b2t8f0wu6ggxj
20 Dec 19
Registration of securities for employees (post-effective amendment)
1:24pm
S-8 POS
k4sn bax76
20 Dec 19
Registration of securities for employees (post-effective amendment)
1:22pm
8-K
oab3j m3ry5
20 Dec 19
Departure of Directors or Certain Officers
7:03am
8-K
pe7q1983y
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
CT ORDER
l7zf iejdn
6 Dec 19
Confidential treatment order
2:08pm
CT ORDER
6byjsb os1z
6 Dec 19
Confidential treatment order
1:52pm
8-K
kydw8zmfv1k wst3omg
26 Nov 19
Entry into a Material Definitive Agreement
4:45pm
4
rgjfcrs
21 Nov 19
ImmunoGen / Thomas Ryll ownership change
4:23pm
8-K
y8ef3 o2q9nq06m
1 Nov 19
ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
6:54am
4
4andg k3r
2 Oct 19
ImmunoGen / Mark Alan Goldberg ownership change
12:00pm
4
e2h1yhlisdq
2 Oct 19
ImmunoGen / DEAN J MITCHELL ownership change
11:59am
8-K
o1n2brm 51uwz3u
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K/A
3fnijk2 mjxk
5 Aug 19
Cost Associated with Exit or Disposal Activities
8:55am
8-K/A
k7rrscv7pcnmns
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
10:33am
8-K
xdwx01eij0g522x0
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
6:38am
4
vdsatne50fsup5k
22 Jul 19
IMMUNOGEN / DAVID G FOSTER ownership change
1:21pm